The ¥4.2bn ($53m) building is expected to improve Astellas’ capacity to manufacture investigational drug substance used in high pharmaceutical activities.
The Building No. 8 will have seven stories with nearly 4,170 m² ground area and will meet the global Good Manufacturing Practice (GMP) for clinical trial material.
The building will also be equipped with flexible facilities to support a multiple line up of manufacturing items and changes in volumes of the demand of investigational drug substance.
The facility will be constructed in consideration with occupational health, safety and environmental preservation by introducing equipment with containment performance and an earthquake-absorbing structure.
The groundbreaking ceremony is scheduled on 22 August 2012 and the work is expected to be completed in late July 2013.
Takahagi Technology Center manufactures drug substance for ethical pharmaceutical products and for clinical trial material.
Astellas is following a global category leader ("GCL") business model to supply valued-added drugs, backed by expertise to select therapeutic areas with a high degree of unmet medical needs.